Unlock instant, AI-driven research and patent intelligence for your innovation.

Prostaglandin compositions for the treatment of erectile dysfunction

A kind of prostaglandin and composition technology, applied in the directions of drug combination, drug delivery, medical preparations of inactive ingredients, etc.

Inactive Publication Date: 2006-05-10
尼克美制药控股有限公司
View PDF16 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although, at present, there is no direct evidence that PGE 1 Can promote the regeneration of cavernous nerve

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Prostaglandin compositions for the treatment of erectile dysfunction
  • Prostaglandin compositions for the treatment of erectile dysfunction
  • Prostaglandin compositions for the treatment of erectile dysfunction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0156] exemplary composition

[0157] Exemplary Composition A was prepared as follows. by dissolving 0.4 parts of prostaglandin E in 5 parts of ethanol 1 (Alprostadil USP) to obtain Part A. Then, 5 parts of 2-(N,N-dimethylamino)-dodecyl propionate were mixed with alcohol-prostaglandin E 1 The solutions were mixed, followed by the addition of 5 parts of ethyl laurate.

[0158] Part B begins by preparing the water / buffer at pH 5.5. Water / buffer was prepared by adding sufficient potassium monohydrogen phosphate to pure water to obtain a 0.1M solution. The pH of the water / buffer was adjusted to 5.5 with a strong base solution (1 N sodium hydroxide) and a strong acid (1 N phosphoric acid). The buffer comprises about 80 parts of the total composition. All parts are by weight.

[0159] Add 0.5 parts of ethyl laurate to the buffer. Then, locust bean gum (in powder form) was dispersed in the buffer and homogenized with a stirring device. Table 1 is a list of ingredients.

[0...

Embodiment 2

[0164] Discover PGE 1 Promotes neurite outgrowth in primary cultures of main pelvic ganglion cells in NADPH-positive dorsal regions of rats. Twenty-four major pelvic ganglia (DCR-MPG) at the dorsal site were dissected from Sprague-Dawley rats. Each sample was plated on a coverslip covered with growth factor-free Matrigel matrix in a Petri dish in a culture medium without serum. PGE 1 (Sigma) was added to the medium at a final concentration of 1, 10, 20, 30, 60 or 100 μmol (uM). 37°C with 5% CO 2 Ganglion cultures were incubated in humidified air. After 96 hours, neurite outgrowth was recorded with a digital camera. Control group (6 samples) without PGE in serum-free medium 1 Incubate on Matrigel matrix.

[0165] Growth factor-free Matrigel matrix (Passaniti, A., et al., Lab. Invest. 1992 67:518-528) was purchased from Becton Dickinson (Mountain View, CA). Cell Culture Grade PGE 1 Available from Sigma Chemical. (St. Louis, MO). RPIM-1640 and other cell culture reagent...

Embodiment 3

[0172] As described in Example 2, 4 pairs of DCR-MPG were isolated and cultured. DCR-MPG on the left was treated with a final concentration of 10 μM PGE 1 treatment, and the one on the right was used as a control. After 96 hours of incubation, it can be seen that with PGE 1 The treated DCR-MPG showed obvious neurite outgrowth compared with the control. PGE 1 The maximum length of the neurite after treatment was 229.33±10.7 μm, while that of the control product was 93.33±28.4 μm (P<0.001).

[0173] Study of PGE with 8 pairs of DCR-MPG 1 Relationship between dose and neurite outgrowth. Add PGE at final concentrations of 10, 20, 30 and 60 μM 1 added to the medium. See Table 2. It can be seen that 30 μM PGE 1 has the greatest effect, and can induce a fiber length of 250±38.1 μm. Significant difference (P<0.05).

[0174] PGE 1 concentration

[0175] The results are summarized in figure 2 middle. There is a dose-dependent effect, PGE 1 At 30 [mu]M, the max...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides compositions for the treatment of erectile dysfunction associated with diabetes, prostatectomy, vesicoprostatectomy, radical cystectomy, rectoabdominoperineal resection, cryotherapy or radiation therapy related neurological diseases and methods.

Description

[0001] Related literature [0002] This application claims priority to US Provisional Application No. 60 / 456,597, filed March 21, 2003, which is incorporated in its entirety by this application. Background technique [0003] Neural control of penile erection involves adrenergic, cholinergic, nonadrenergic, and noncholinergic (NANC) systems in the cavernous nerves that are isolated from the prostatic capsule. The difference is only a few millimeters. Common treatments for prostate and bladder cancer include bladder prostatectomy, radical cystectomy, rectoabdominoperineal resection, radical prostatectomy, cryotherapy, and radiation therapy. These treatments are some of the most common causes of erectile dysfunction (ED) in the United States. The neurogenic erectile dysfunction exhibited by these patients is thought to result from damage to the cavernous nerves that innervate the vascular smooth muscle cells of the corpus cavernosum. [0004] Retropubic prostatectomy (RPP) has...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/5575A61K9/00A61K47/00A61K47/02A61K47/10A61K47/14A61K47/18A61K47/26A61K47/36A61P15/10
CPCA61K9/0014A61K9/0034A61K31/5575A61K47/02A61K47/10A61K47/14A61K47/18A61K47/26A61K47/36A61P15/10A61K31/557
Inventor 林桂亭Y.·约瑟夫·莫吕明启郭应禄
Owner 尼克美制药控股有限公司
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com